Price and purchase method of Akumidis

Acoramidis (acoramidis), trade nameAttruby, is an innovative oral prescription drug specifically indicated for the treatment of amyloid cardiomyopathy (ATTR-CM) mediated by wild-type or hereditary transthyretin (TTR). The disease is a progressive and fatal condition characterized by misfolding and deposition of the TTR protein in the heart, resulting in impaired myocardial function and possible heart failure.

Attruby exerts its therapeutic effect by stabilizing the structure of TTR protein in the blood. It binds to the thyroxine binding site of TTR, thereby slowing down the rate at which TTR tetramers are broken down into monomers and inhibiting the subsequent amyloidosis process. This mechanism helps reduce the deposition of harmful amyloid proteins in the heart, thereby slowing the progression of the disease, reducing cardiovascular-related hospitalization and mortality, and significantly improving patients' quality of life.

As a nearly completely (≥90%) TTR selective stabilizer, Attruby can target the TTR protein efficiently and specifically, minimizing unnecessary side effects. The drug was approved by the U.S. Food and Drug Administration ( an>FDA) for the treatment of adults with wild-type or hereditary TTR-mediated ATTR-CM cardiomyopathy. This approval is based on positive results from the ATTRibute-CMPhase 3 clinical study, which showed >30Over the course of 30 months of treatment, Attruby showed significant therapeutic effects on key indicators such as the Kansas City Cardiomyopathy Questionnaire and the Six-Minute Walk Test.

In addition,Attruby also showed good results in controlling heart failure markersNT-proBNP. Research shows that acceptanceThe increase in NT-proBNP levels in Attruby-treated patients was about half that of the placebo group, meaning that after 30 months of treatment, treated patients had lower rates of heart failure than untreated patients. This finding further confirms the effectiveness and safety of Attruby in treating ATTR-CM.

Overall, alcomideps (Attruby) is a breakthrough therapy for ATTR-CM, which provides patients with new treatment options and hope by stabilizing TTR protein and slowing down disease progression.

It should be noted that as a new drug approved by FDA at the end of 2024 , it is currently difficult to obtain it directly at home and abroad. If patients have specific questions about alcomidex, it is recommended to consult a professional overseas medical consultant for more information. Regarding price, due to market conditions and differences in different regions, the specific price needs further confirmation.

Reference link:https://www.rxlist.com/attruby-drug.htm